Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head trial in diabetic macular oedema (DME) or wet (neovascular) age-related macular degeneration (wAMD).
In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, with improvements being 75% greater after one week and 50% greater after 12 weeks, as measured using optical coherence tomography (OCT). Vabysmo is also a VEGF/Ang2 bispecific antibody.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, nearly 90% of patients treated with OLN324 achieved absence of DME at week 12, as compared to 57% of Vabysmo patients.
In wAMD, all treatment groups yielded equivalent anatomic outcomes, with rapid improvements in OCT and central subfield thickness (CST) as early as week 1. These improvements were sustained through week 12.
Patients across all treatment groups experienced rapid and sustained mean gains in vision, but numerically greater improvements were seen in those treated with OLN324 in both DME and wAMD.
Based on the data, Ollin, which is partnered with Innovent Biologics on the development of OLN324, will advance the drug to Phase III trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis study marks the first time a therapy has demonstrated superior anatomic efficacy to Vabysmo in a head-to-head, randomised clinical trial, said Dr Jason Ehrlich, co-founder and CEO of Ollin Biosciences.
Ehrlich added: “These data validate that a higher potency, higher molar dose, smaller format VEGF/Ang2 bispecific can more fully realise the therapeutic potential of dual VEGF and Ang2 inhibition.”
Sales for Vabysmo in DME and wAMD are rapidly increasing as the drug begins to challenge the dominance of Regeneron’s Eylea (aflibercept) in the ophthalmology market. Vabysmo generated $2.25bn in sales in the first half of 2025.
Ollin plans to discuss the JADE study and additional pipeline and corporate progress during its upcoming presentation at the 44th Annual JP Morgan Healthcare Conference, taking place between 12-15 January.
Full results of the study will be presented for the first time at the upcoming Angiogenesis, Exudation, and Degeneration 2026 symposium on 7 February.
wAMD options broadening
REGENEXBIO has concluded enrolment in two pivotal trials of its wAMD gene therapy, surabgene lomparvovec.
Eyepoint Pharmaceuticals is also evaluating data for its candidate Duravyu (vorolanib intravitreal insert), in the pivotal LUCIA trial in wAMD. This follows enrolling patients in the first study, LUGANO, in May 2025. The company anticipates releasing topline data soon after the outcomes from LUGANO are released, which are anticipated in mid-2026.
According to GlobalData, parent company of Clinical Trials Arena, the AMD market in the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $7.8bn in 2024 to $20.5bn in 2034.
GlobalData’s latest report, “Age-Related Macular Degeneration: Seven-Market Drug Forecast and Market Analysis,” reveals that the market’s growth will be supported by the anticipated launch of 26 novel pipeline agents, coupled with the growing AMD population throughout the forecast period.
Meanwhile, GlobalData projects the diagnosed prevalent cases of DME across the 7MM to grow from 2.89 million in 2024 to 3.46 million by 2034.
